Research programme: anti-CEA fusion proteins - Cancer Research Technologies/Novozymes/UCL

Drug Profile

Research programme: anti-CEA fusion proteins - Cancer Research Technologies/Novozymes/UCL

Alternative Names: Anti-CEA scFv fusion proteins; MFE 23-albumin fusion protein; MFE-23

Latest Information Update: 01 Aug 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology; University College London
  • Developer Cancer Research Technology; Novozymes Delta; University College London
  • Class Albumins; Immunoglobulin fusion proteins; Immunoglobulin Fv fragments; Recombinant fusion proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 01 Aug 2012 No development reported - Early research for Solid tumours in United Kingdom (Parenteral)
  • 11 Sep 2007 Early research in Solid tumours in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top